Vanguard Global Advisers
RLAY icon

Vanguard Global Advisers’s Relay Therapeutics RLAY Stock Holding History

Vanguard Global Advisers’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Buy
89,095
+14,016
+19% +$203K ﹤0.01% 1397
2026
Q1 		$747K Buy
+75,079
New +$672K ﹤0.01% 1809

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Vanguard Global Advisers's RLAY Position: Q2 2026 in Review

Vanguard Global Advisers increased its Relay Therapeutics (RLAY) stake by 19% in Q2 2026, buying an estimated $203K and bringing the position to 89,095 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Vanguard Global Advisers first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Vanguard Global Advisers held 89,095 shares of Relay Therapeutics worth $1.67M as of Q2 2026.
  • Vanguard Global Advisers bought 14,016 Relay Therapeutics shares in Q2 2026, an estimated $203K.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1397 holding.
  • Vanguard Global Advisers first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.